Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Integra LifeSciences (IART) reported $382.42 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 0.7%. EPS of $0.76 for the same period compares to $0.86 a year ago.
The reported revenue represents a surprise of -1.35% over the Zacks Consensus Estimate of $387.67 million. With the consensus EPS estimate being $0.78, the EPS surprise was -2.56%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Revenue Growth: -0.4% versus the six-analyst average estimate of 0.7%.
Revenue- Codman Specialty Surgical- Total: $268.21 million versus $267.62 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +7.4% change.
Revenue- Tissue Technologies- Total: $114.22 million versus $120 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -15.6% change.
Revenue- Tissue Technologies- Private Label: $26.15 million versus $21.83 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -15% change.
Revenue- Codman Specialty Surgical- Instruments: $58.98 million versus the five-analyst average estimate of $63.09 million. The reported number represents a year-over-year change of +5.4%.
Revenue- Codman Specialty Surgical- Neurosurgery: $209.23 million versus $204.52 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
Revenue- Tissue Technologies- Wound Reconstruction and Care: $88.07 million compared to the $98.67 million average estimate based on five analysts. The reported number represents a change of -15.8% year over year.
View all Key Company Metrics for Integra here>>>
Shares of Integra have returned -2.2% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report
